Anteris Technologies Global Corp. Updates Stockholders
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is making strides in the field of structural heart health by taking important steps in its corporate governance. The company focuses on designing and developing advanced medical devices aimed at improving heart functionality and overall patient care. Recently, the company convened a Special Meeting of Stockholders, originally scheduled for September 18, 2025, but was adjourned due to a lack of quorum.
Adjournment of Special Meeting Explained
The special meeting has been rescheduled to September 29, 2025. The intent of this adjournment is to give stockholders additional time to cast their votes regarding key proposals outlined in the company’s Proxy Statement. This statement is crucial as it outlines the initiatives and strategies planned for the future.
Importance of Stockholder Participation
The company urges stockholders to actively participate in the voting process, emphasizing that their votes are vital for determining the outcomes of the proposals. Stockholders who have already cast their votes do not need to take further action unless they wish to change their decision.
Voting Instructions for Stockholders
Stockholders who haven’t yet voted can find detailed instructions in the company’s Proxy Statement. The deadlines for voting are critical; proxies submitted online or via phone must be received by 11:59 p.m. Eastern time on September 28, 2025. For those sending their votes by mail, the necessary documents should reach the company by close of business on September 26, 2025.
CDIs Voting Process
For holders of CHESS Depositary Interests (CDIs), it’s important to note that they must direct CDN to vote. Completed voting forms should be submitted before 5:00 p.m. Central time on September 25, 2025, to ensure that all votes are counted.
Further Insights on Anteris Technologies
Anteris Technologies Global Corp. is at the forefront of heart health technology with its flagship product, the DurAVR Transcatheter Heart Valve (THV). This innovative valve is designed to treat aortic stenosis, a condition marked by the narrowing of the aortic valve, posing serious health risks. The DurAVR THV is unique as it mimics the function of a healthy human aortic valve and is constructed using Anteris’ proprietary ADAPT tissue technology.
Positive Impact on Patients
With FDA clearance and clincal success in over 55,000 patients, the DurAVR THV aims to enhance the standard of care provided to patients suffering from structural heart diseases. This approach illustrates Anteris’ commitment to improving patient outcomes through innovative, high-quality medical solutions.
Contacting Anteris Technologies
Anteris encourages stockholders and interested parties to reach out with any inquiries. The Investor Relations team is readily available for support; they can be contacted via the email provided or by calling the dedicated phone lines. Having knowledgeable experts like Debbie Ormsby and Malini Chatterjee on hand reinforces the company's commitment to transparency and accessibility.
Frequently Asked Questions
What led to the adjournment of the meeting?
The meeting was adjourned due to a lack of quorum, meaning not enough stockholders were present to conduct business safely.
When is the new date for the Special Meeting?
The rescheduled Special Meeting will now take place on September 29, 2025.
How can stockholders vote on the proposals?
Details for voting can be found in the Proxy Statement, with options to vote via mail, internet, or phone before the deadlines.
What is the significance of the DurAVR THV?
The DurAVR THV represents a major advancement in treating aortic stenosis and shows significant promise in improving patient outcomes.
Who can stockholders contact for further information?
Stockholders can reach out to the Investor Relations team via the company’s email or by phone for more details regarding their votes and proposals.
